HBI-2438

· HUYABIO International, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HBI-2438, covering 2025-09-24 to 2025-09-24. Get the full timeline:

Most recent: Clinical Trial Update: A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation [Phase 1]